NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The program is supported by a grant from the Children's Cancer Research Fund (CCRF) to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to address the challenge of achieving therapeutic drug concentrations within brain tumors. While convection-enhanced delivery (CED) bypasses the blood-brain barrier, rapid drug clearance limits therapeutic benefit. The Mayo team will evaluate a combination therapy strategy to enhance intratumoral drug retention by modulating drug efflux mechanisms, prolonging therapeutic exposure. The project begins with large animal studies and may expand to human studies later.
The study will use NeuroOne's investigational drug delivery neural device, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach enables targeted therapy with real-time physiologic monitoring, offering insight into drug delivery and effects on the neural environment. The CCRF award advances this approach toward clinical evaluation and expands NeuroOne's drug delivery initiatives, reflecting growing interest from academic investigators and biopharmaceutical companies.
David Wambeke, Chief Business Officer of NeuroOne, stated: "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording."
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System, and OneRF Trigeminal Nerve Ablation System. The company is also engaged in research for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
This press release includes forward-looking statements subject to risks and uncertainties. For details, see NeuroOne's filings with the Securities and Exchange Commission.
